Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 18,296 as of Wednesday, May 20, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,497 issues advancing vs. 1,463 declining with 190 unchanged. The Health Services industry currently sits up 0.1% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Baxter International ( BAX), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Edwards Lifesciences ( EW) is one of the companies pushing the Health Services industry higher today. As of noon trading, Edwards Lifesciences is up $1.90 (1.4%) to $132.98 on average volume. Thus far, 498,645 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $131.04-$134.27 after having opened the day at $131.43 as compared to the previous trading day's close of $131.08. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $14.2 billion and is part of the health care sector. Shares are up 2.9% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Edwards Lifesciences Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.